Zai Lab Limited (HKG:9688)
27.74
+0.14 (0.51%)
Aug 15, 2025, 4:08 PM HKT
Zai Lab Revenue
Zai Lab had revenue of $109.98M USD in the quarter ending June 30, 2025, with 9.43% growth. This brings the company's revenue in the last twelve months to $427.80M, up 32.56% year-over-year. In the year 2024, Zai Lab had annual revenue of $398.99M with 49.59% growth.
Revenue (ttm)
$427.80M
Revenue Growth
+32.56%
P/S Ratio
9.26
Revenue / Employee
$228.89K
Employees
1,869
Market Cap
31.11B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines | 35.81B |
Hansoh Pharmaceutical Group Company | 13.05B |
JD Health International | 71.34B |
Innovent Biologics | 10.03B |
Akeso | 2.26B |
Sino Biopharmaceutical | 30.72B |
WuXi Biologics | 19.87B |
CSPC Pharmaceutical Group | 28.99B |
Zai Lab News
- 8 days ago - Zai Lab reaffirms $560M-$590M 2025 revenue target as VYVGART and pipeline drive growth - Seeking Alpha
- 8 days ago - Zai Lab Limited (ZLAB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates - Business Wire
- 9 days ago - This Cancer Treatment Stock Nears A Buy Point As Quarterly Results Loom - Investor's Business Daily
- 5 weeks ago - Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025 - Business Wire
- 6 weeks ago - Amgen, Zai Lab succeed in gastric cancer study - Seeking Alpha
- 6 weeks ago - Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer - Business Wire
- 2 months ago - Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025 - Business Wire